Monday, June 30, 2025 6/30/2025

The role of HbF decline and its determinants on Sickle Cell Disease expression in the first three years of life.

Award Number: K43TW011167
ORGANIZATION: FOGARTY INTERNATIONAL CENTER
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2019
PERIOD OF PERFORMANCE END DATE: 04/30/2024

Group Awards By:

View Award Description

The role of HbF decline and its determinants on Sickle Cell Disease expression in the first three years of life. - PROJECT SUMMARY Background: Tanzania has included SCD as an important public health condition in the country’s non communicable diseases (NCD) strategy. Tanzania ranks 5th, after Nigeria, DRC, India and Angola in countries with the highest numbers of SCD births. Recent estimates show that over 10,000 SCD children under 5 years of age (U5) die annually in Tanzania, representing 6.6% of overall U5 deaths. Developmentally-regulated physiological and pathological changes occur in early childhood that may impact on the natural history of SCD. As hemoglobin γ→β globin gene switching occurs; sickle haemoglobin (HbS) gradually replaces fetal haemoglobin (HbF). Disease manifestations, including haemolysis, painful episodes, anaemia, start during this period and continues throughout life. Haemaglobin switching and HbF decline plays a central role in SCD disease expression. The determinants of HbF decline, the spectrum of variation of HbF decline and how these relate to disease expression in the first three years of life is not clear. Specific Aims: (1). To determine the association of HbF decline with SCD clinical expression in the first three years of life (2). To determine the genetic factors associated with HbF decline in babies with and without SCD (3). To study the variation of the pattern and rate of HbF decline in babies with and without SCD. Significance of the study and relevance to public health: The ultimate goal of HbF research is the development of interventions. Understanding the role of HbF decline in SCD disease expression in the early life will inform on the time point for HbF interventions. In addition, elucidating the genetic determinants of HbF decline will highlight the mechanism of HbF switching/ synthesis and hence development of interventions to induce HbF synthesis in adulthood. The unique features and innovation of the project: This study will establish the first SCD birth cohort in Tanzania. The proposed study will follow 400 babies with and without SCD for three years to investigate SCD expression and HbF decline. The methodology: We will use existing newborn screening and immunization platforms to enroll and follow babies from birth up to three years. Gene expression profiling will be used to interrogate genes associated with HbF decline while targeted next generation sequencing will investigate known HbF coding and non coding variants. We will investigate whether genetic factors influence the spectrum of variation of HbF decline and clinical expression. Expected results: To date, there is only one available SCD drug, hydroxyurea, that results in increased HbF levels. Findings from this study will increase knowledge on the opportunities to develop additional interventions as well as better administration of hydroxyurea.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	000	5	9/3/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $87,860 )
2023	2023	MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	000	5	3/20/2023	NON-COMPETING CONTINUATION	$87,860
														Subtotal = $87,860

Issue Date FY: 2022 ( Subtotal = $138,939 )
2022	2022	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM	NULL			TZA	International Research and Research Training	000	4	4/1/2022	NON-COMPETING CONTINUATION	$88,940
2022	2022	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM	NULL			TZA	International Research and Research Training	001	4	9/7/2022	SUPPLEMENT FOR EXPANSION	$49,999
														Subtotal = $138,939

Issue Date FY: 2021 ( Subtotal = $85,700 )
2021	2021	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	000	3	3/30/2021	NON-COMPETING CONTINUATION	$85,700
														Subtotal = $85,700

Issue Date FY: 2020 ( Subtotal = $132,680 )
2020	2020	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	002	2	9/4/2020	SUPPLEMENT FOR EXPANSION	$43,740
2020	2020	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	001	2	5/26/2020	NON-COMPETING CONTINUATION	$0
2020	2020	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	000	2	4/30/2020	NON-COMPETING CONTINUATION	$88,940
														Subtotal = $132,680

Issue Date FY: 2019 ( Subtotal = $88,940 )
2019	2019	MUHIMBILI UNIVERSITY OF HEALT H AND ALLIED SCIENCES	UNITED NATIONS ROAD	DAR ES SALAAM				TZA	International Research and Research Training	000	1	7/31/2019	NEW	$88,940
														Subtotal = $88,940

Grand Total All Awards = $534,119

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The role of HbF decline and its determinants on Sickle Cell Disease expression in the first three years of life.

Award Number: K43TW011167

ORGANIZATION: FOGARTY INTERNATIONAL CENTER

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2019

PERIOD OF PERFORMANCE END DATE: 04/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer